AstraZeneca (AZN)

Sector:

Pharma and Biotech

Index:

FTSE 100

10,684.00p
   
  • Change Today:
    -16.00p
  • 52 Week High: 13,276.00p
  • 52 Week Low: 9,667.00p
  • Currency: UK Pounds
  • Shares Issued: 1,550.66m
  • Volume: 131,200
  • Market Cap: £165,672m
  • RiskGrade: 123

AstraZeneca Overview

A world-leading pharmaceutical group, AstraZeneca was created in 1999 via the merger of Sweden's Astra and the UK's Zeneca, which had been demerged from chemicals group ICI in 1993. About half of its total sales are generated from the US, with over a third of revenues coming from its gastrointestinal treatments such as Prilosec (Losec) and Nexium.

1 Day Chart

1 Day Chart

6 Month Chart

6 Month Chart
Barclays logo

Digital Look Charts Sponsored by Barclays Stockbrokers

AstraZeneca Financials

Latest F'cast
Div Yield 2.1% 0.0%
Div Cover 2.6 2.8
Op Mrgn 18.5% 32.1%
ROCE 60.7%  
Latest F'cast
P/E 17.7 15.8
PEG 1.4 1.6
Pr/Revenue 4.2 2.8
Pr/Book 5.5  
Latest F'cast
Revenue 18.0% -21.5%
PBT 26.0% 56.6%
EPS 13.1% 9.8%
DPS 6.9% -42.8%

AstraZeneca Fundamentals

Year Ending Revenue ($m) Pre-tax ($m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-20 26,617.00 3,916.00 244.00¢ 40.7 0.3 +137% 280.00¢ 2.8%
31-Dec-21 37,417.00 (265.00) 8.00¢ 1,470.3 n/a -97% 287.00¢ 2.4%
31-Dec-22 44,351.00 2,501.00 212.00¢ 71.7 0.0 +2,550% 290.00¢ 1.9%
31-Dec-23 45,811.00 6,899.00 726.00¢ 19.8 0.1 +242% 290.00¢ 2.0%
31-Dec-24 54,073.00 8,691.00 821.00¢ 17.3 1.3 +13% 310.00¢ 2.2%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

AstraZeneca Forecasts

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-25 57,559.42 18,453.09 669.44p 16.0 1.6 +10% 240.27p 0.0%
31-Dec-26 61,106.20 20,674.08 757.77p 14.1 1.1 +13% 252.70p 0.0%
31-Dec-27 64,584.86 22,654.33 836.68p 12.8 1.2 +10% 263.71p 0.0%

Copyright © 2025 FactSet Research Systems Inc. All rights reserved.

AstraZeneca Company Announcements

Fixed-duration Calquence approved in EU for 1L CLL 06-Jun-2025 07:00 RNS
Block listing Interim Review 02-Jun-2025 15:05 RNS
Total Voting Rights 02-Jun-2025 15:00 RNS

AstraZeneca ShareCast News

AstraZeneca's Calquence receives European Commis... 06-Jun-2025 ShareCast
EU recommends AstraZeneca bladder cancer treatme... 27-May-2025 ShareCast
London close: Stocks finish choppy week in the b... 16-May-2025 ShareCast

AstraZeneca Top Newspaper Links

Fighting Frenchman shows us how as he ensures As... 30-Dec-2014 Daily Mail
Exclusive: UK firms vie for share of £170bn in A... 08-Dec-2014 The Independent
MARKET REPORT: Ariad on the up amid growing spec... 04-Dec-2014 Daily Mail

Latest AstraZeneca Director Deals

Traded Action Notifier PriceAmountValue
21-May-25 Transfer From Pascal Soriot 0.000p 8,970 £0.00
30-Apr-25 Buy Karen Knudsen 5,376.72p 1,400 £75,274.07

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.

 

AstraZeneca Market Data

Currency UK Pounds
Share Price 10,684.00p
Change Today -16.00p
% Change -0.15 %
52 Week High 13,276.00p
52 Week Low 9,667.00p
Volume 131,200
Shares Issued 1,550.66m
Market Cap £165,672m
RiskGrade 123

AstraZeneca Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
93.77% below the market average93.77% below the market average93.77% below the market average93.77% below the market average93.77% below the market average
91.3% below the sector average91.3% below the sector average91.3% below the sector average91.3% below the sector average91.3% below the sector average
Price Trend
16.68% below the market average16.68% below the market average16.68% below the market average16.68% below the market average16.68% below the market average
24.44% above the sector average24.44% above the sector average24.44% above the sector average24.44% above the sector average24.44% above the sector average
Income
61.75% below the market average61.75% below the market average61.75% below the market average61.75% below the market average61.75% below the market average
14.29% below the sector average14.29% below the sector average14.29% below the sector average14.29% below the sector average14.29% below the sector average
Growth
86.34% above the market average86.34% above the market average86.34% above the market average86.34% above the market average86.34% above the market average
100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average

What The Brokers Say

Strong Buy 10
Buy 14
Neutral 5
Sell 0
Strong Sell 0
Total 29
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

AstraZeneca Dividends

  Latest Previous
  2nd Interim 1st Interim
Ex-Div 20-Feb-25 08-Aug-24
Paid 24-Mar-25 09-Sep-24
Amount 210.00¢ 100.00¢

Trades for 06-Jun-2025

Time Volume / Share Price
12:31 180 @ 10,686.00p
12:31 58 @ 10,684.00p
12:31 58 @ 10,682.00p
12:30 2 @ 10,683.72p
12:30 69 @ 10,684.00p

AstraZeneca Key Personnel

Chair Michel Demare

Top of Page